Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
Year: 2019
Type: article
Abstract: Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.
Source: The Oncologist
Institutions: Duke Medical Center, Duke Cancer Institute, Exelixis (United States), Duke University, Massachusetts General Hospital, Washington University in St. Louis, Alvin J. Siteman Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Kansas, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $1,450
Awards: Washington University/ Siteman Cancer Center Lead Academic Site, Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center, G2051006376, G2215807464, G2453551107, G289723095, G2995938707, G3053988604, Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center, G4185274752, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, G7961793835, G8225661566, Alliance for Clinical Trials in Oncology Operations Center, G9000003249, G9000003380, G9000206464, G9000232080, G9000252023, G9000297436, Cancer Center Support Grant
OpenAlex ID: W2967985682